EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tilray Brands's EBITDA for the
three
months ended in Feb. 2026 was €-1.3 Mil. Tilray Brands's Revenue for the
three
months ended in Feb. 2026 was €174.9 Mil. Therefore, Tilray Brands's EBITDA margin for the quarter that ended in Feb. 2026 was -0.75%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tilray Brands EBITDA Margin % Related Terms
Tilray Brands EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tilray Brands's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WBO:TLR2 vs IRWD, BIOA, ESPR: EBITDA Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tilray Brands's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tilray Brands EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tilray Brands's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tilray Brands's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tilray Brands (WBO:TLR2) has a EBITDA Margin % of -0.75% as of Feb. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tilray Brands and its competitors. According to the industry distribution chart, Tilray Brands ranks #894 out of 955 companies in the Drug Manufacturers industry, placing it in the top 93.6%.
Is Tilray Brands' EBITDA Margin % too high?
Tilray Brands' current EBITDA Margin % is -0.75%. Based on the distribution chart, Tilray Brands ranks #894 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Tilray Brands has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tilray Brands' EBITDA Margin % compare to IRWD and BIOA?
According to the Drug Manufacturers industry distribution chart, Tilray Brands ranks #894 out of 955 companies for EBITDA Margin %. This places Tilray Brands in the lower half of its industry. The industry median EBITDA Margin % is 12.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tilray Brands and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tilray Brands's current EBITDA Margin % is -0.75%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tilray Brands stock overvalued right now?
Based on GuruFocus' analysis, Tilray Brands (WBO:TLR2) is currently considered Possible Value Trap. The stock's GF Value™ is €10.82, compared to a current price of €3.92 — trading 63.8% below its estimated fair value. The current EBITDA Margin % is -0.75%. Tilray Brands' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tilray Brands (WBO:TLR2), the current EBITDA Margin % is -0.75% as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tilray Brands (WBO:TLR2) Overvalued in 2026?
Based on GuruFocus' analysis, Tilray Brands stock appears to be undervalued.
The current stock price of €3.92 is trading 63.8% below its estimated GF Value™ of €10.82.
GuruFocus considers Tilray Brands to be Possible Value Trap.
Key valuation signals for WBO:TLR2:
EBITDA Margin %: -0.75%
GF Value™: €10.82 vs. price of €3.92 (63.8% below fair value)
No single metric tells the full story. See the WBO:TLR2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.
55GF Score
Get the complete analysis for WBO:TLR2
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:TLR2 has been successfully added to your 
